請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/45695
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳青周 | |
dc.contributor.author | Pei-Hua Lin | en |
dc.contributor.author | 林佩樺 | zh_TW |
dc.date.accessioned | 2021-06-15T04:44:45Z | - |
dc.date.available | 2015-09-13 | |
dc.date.copyright | 2010-09-13 | |
dc.date.issued | 2010 | |
dc.date.submitted | 2010-08-09 | |
dc.identifier.citation | Aguilar, F., C. C. Harris, et al. (1994). 'Geographic variation of p53 mutational profile
in nonmalignant human liver.' Science 264(5163): 1317-1319. Ando, T., T. Kawabe, et al. (2001). 'Involvement of the interaction between p21 and proliferating cell nuclear antigen for the maintenance of G2/M arrest after DNA damage.' J Biol Chem 276(46): 42971-42977. Armeanu, S., M. Bitzer, et al. (2005). 'Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.' Cancer Res 65(14): 6321-6329. Arteaga, C. L. (2007). 'HER3 and mutant EGFR meet MET.' Nat Med 13(6): 675-677. Avila, M. A., C. Berasain, et al. (2006). 'New therapies for hepatocellular carcinoma.' Oncogene 25(27): 3866-3884. Baylin, S. B. and J. E. Ohm (2006). 'Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?' Nat Rev Cancer 6(2): 107-116. Bean, J., C. Brennan, et al. (2007). 'MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.' Proc Natl Acad Sci U S A 104(52): 20932-20937. Bellacosa, A., C. C. Kumar, et al. (2005). 'Activation of AKT kinases in cancer: implications for therapeutic targeting.' Adv Cancer Res 94: 29-86. Berasain, C., J. Castillo, et al. (2007). 'New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system.' Liver Int 27(2): 174-185. Berasain, C., E. R. Garcia-Trevijano, et al. (2005). 'Amphiregulin: an early trigger of liver regeneration in mice.' Gastroenterology 128(2): 424-432. Berasain, C., E. R. Garcia-Trevijano, et al. (2005). 'Novel role for amphiregulin in protection from liver injury.' J Biol Chem 280(19): 19012-19020. Berasain, C., M. J. Perugorria, et al. (2009). 'The epidermal growth factor receptor: a link between inflammation and liver cancer.' Exp Biol Med (Maywood) 234(7): 713-725. Blagosklonny, M. V., R. Robey, et al. (2002). 'Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity.' Mol Cancer Ther 1(11): 937-941. Block, T. M., A. S. Mehta, et al. (2003). 'Molecular viral oncology of hepatocellular carcinoma.' Oncogene 22(33): 5093-5107. Boccaccio, C. and P. M. Comoglio (2006). 'Invasive growth: a MET-driven genetic programme for cancer and stem cells.' Nat Rev Cancer 6(8): 637-645. Bolden, J. E., M. J. Peart, et al. (2006). 'Anticancer activities of histone deacetylase inhibitors.' Nat Rev Drug Discov 5(9): 769-784. Borlak, J., T. Meier, et al. (2005). 'Epidermal growth factor-induced hepatocellular carcinoma: gene expression profiles in precursor lesions, early stage and solitary tumours.' Oncogene 24(11): 1809-1819. Borowiak, M., A. N. Garratt, et al. (2004). 'Met provides essential signals for liver regeneration.' Proc Natl Acad Sci U S A 101(29): 10608-10613. Bowen, D. G. and C. M. Walker (2005). 'Adaptive immune responses in acute and chronic hepatitis C virus infection.' Nature 436(7053): 946-952. Bressac, B., M. Kew, et al. (1991). 'Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa.' Nature 350(6317): 429-431. Breuhahn, K., T. Longerich, et al. (2006). 'Dysregulation of growth factor signaling in human hepatocellular carcinoma.' Oncogene 25(27): 3787-3800. Bruix, J., L. Boix, et al. (2004). 'Focus on hepatocellular carcinoma.' Cancer Cell 5(3): 215-219. Burgess, T., A. Coxon, et al. (2006). 'Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.' Cancer Res 66(3): 1721-1729. Campbell, M. R., D. Amin, et al. (2010). 'HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.' Clin Cancer Res 16(5): 1373-1383. Cao, B., Y. Su, et al. (2001). 'Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models.' Proc Natl Acad Sci U S A 98(13): 7443-7448. Castillo, J., E. Erroba, et al. (2006). 'Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells.' Cancer Res 66(12): 6129-6138. Cayrol, C., M. Knibiehler, et al. (1998). 'p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells.' Oncogene 16(3): 311-320. Chen, B. F., C. J. Liu, et al. (2006). 'High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases.' Gastroenterology 130(4): 1153-1168. Chen, L., W. Fischle, et al. (2001). 'Duration of nuclear NF-kappaB action regulated by reversible acetylation.' Science 293(5535): 1653-1657. Chen, Y., M. C. Lin, et al. (2007). 'Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin.' Hepatology 46(1): 200-208. Cheng, A. L., Y. K. Kang, et al. (2009). 'Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.' Lancet Oncol 10(1): 25-34. Chiba, T., O. Yokosuka, et al. (2004). 'Identification of genes up-regulated by histone deacetylase inhibition with cDNA microarray and exploration of epigenetic alterations on hepatoma cells.' J Hepatol 41(3): 436-445. Chisari, F. V. (2005). 'Unscrambling hepatitis C virus-host interactions.' Nature 436(7053): 930-932. Chou, C. W. and C. C. Chen (2008). 'HDAC inhibition upregulates the expression of angiostatic ADAMTS1.' FEBS Lett 582(29): 4059-4065. Ciardiello, F. and G. Tortora (2008). 'EGFR antagonists in cancer treatment.' N Engl J Med 358(11): 1160-1174. Citri, A. and Y. Yarden (2006). 'EGF-ERBB signalling: towards the systems level.' Nat Rev Mol Cell Biol 7(7): 505-516. Comporti, M., B. Arezzini, et al. (2005). 'F2-isoprostanes stimulate collagen synthesis in activated hepatic stellate cells: a link with liver fibrosis?' Lab Invest 85(11): 1381-1391. Cooper, C. S., M. Park, et al. (1984). 'Molecular cloning of a new transforming gene from a chemically transformed human cell line.' Nature 311(5981): 29-33. Dangond, F., D. A. Hafler, et al. (1998). 'Differential display cloning of a novel human histone deacetylase (HDAC3) cDNA from PHA-activated immune cells.' Biochem Biophys Res Commun 242(3): 648-652. Date, K., K. Matsumoto, et al. (1998). 'Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor.' Oncogene 17(23): 3045-3054. Daveau, M., M. Scotte, et al. (2003). 'Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma.' Mol Carcinog 36(3): 130-141. Deribe, Y. L., P. Wild, et al. (2009). 'Regulation of epidermal growth factor receptor trafficking by lysine deacetylase HDAC6.' Sci Signal 2(102): ra84. Derksen, P. W., D. J. de Gorter, et al. (2003). 'The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma.' Leukemia 17(4): 764-774. Deroanne, C. F., K. Bonjean, et al. (2002). 'Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling.' Oncogene 21(3): 427-436. Desbois-Mouthon, C., A. Baron, et al. (2009). 'Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.' Clin Cancer Res 15(17): 5445-5456. Desbois-Mouthon, C., W. Cacheux, et al. (2006). 'Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib.' Int J Cancer 119(11): 2557-2566. Ding, X., L. Y. Yang, et al. (2004). 'ADAM17 mRNA expression and pathological features of hepatocellular carcinoma.' World J Gastroenterol 10(18): 2735-2739. Dokmanovic, M. and P. A. Marks (2005). 'Prospects: histone deacetylase inhibitors.' J Cell Biochem 96(2): 293-304. Drucker, C., W. Parzefall, et al. (2006). 'Non-parenchymal liver cells support the growth advantage in the first stages of hepatocarcinogenesis.' Carcinogenesis 27(1): 152-161. Drummond, D. C., C. O. Noble, et al. (2005). 'Clinical development of histone deacetylase inhibitors as anticancer agents.' Annu Rev Pharmacol Toxicol 45: 495-528. Duncan, S. A. (2003). 'Mechanisms controlling early development of the liver.' Mech Dev 120(1): 19-33. Eder, J. P., G. F. Vande Woude, et al. (2009). 'Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.' Clin Cancer Res 15(7): 2207-2214. Efimova, E. A., M. Glanemann, et al. (2004). 'Effects of human hepatocyte growth factor on the proliferation of human hepatocytes and hepatocellular carcinoma cell lines.' Eur Surg Res 36(5): 300-307. El-Serag, H. B. (2004). 'Hepatocellular carcinoma: recent trends in the United States.' Gastroenterology 127(5 Suppl 1): S27-34. El-Serag, H. B. and K. L. Rudolph (2007). 'Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.' Gastroenterology 132(7): 2557-2576. Engelman, J. A. and P. A. Janne (2008). 'Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.' Clin Cancer Res 14(10): 2895-2899. Engelman, J. A., K. Zejnullahu, et al. (2007). 'MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.' Science 316(5827): 1039-1043. Fabregat, I., C. Roncero, et al. (2007). 'Survival and apoptosis: a dysregulated balance in liver cancer.' Liver Int 27(2): 155-162. Fan, S., Y. X. Ma, et al. (2000). 'The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3' kinase.' Oncogene 19(18): 2212-2223. Farazi, P. A. and R. A. DePinho (2006). 'Hepatocellular carcinoma pathogenesis: from genes to environment.' Nat Rev Cancer 6(9): 674-687. Farooq, M., K. N. Sulochana, et al. (2008). 'Histone deacetylase 3 (hdac3) is specifically required for liver development in zebrafish.' Dev Biol 317(1): 336-353. Fausto, N., J. S. Campbell, et al. (2006). 'Liver regeneration.' Hepatology 43(2 Suppl 1): S45-53. Feitelson, M. A., B. Sun, et al. (2002). 'Genetic mechanisms of hepatocarcinogenesis.' Oncogene 21(16): 2593-2604. Ferracini, R., P. Longati, et al. (1991). 'Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase.' J Biol Chem 266(29): 19558-19564. Firon, M., M. Shaharabany, et al. (2000). 'Dominant negative Met reduces tumorigenicity-metastasis and increases tubule formation in mammary cells.' Oncogene 19(20): 2386-2397. Furumai, R., A. Matsuyama, et al. (2002). 'FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases.' Cancer Res 62(17): 4916-4921. Furuse, J. (2008). 'Growth factors as therapeutic targets in HCC.' Crit Rev Oncol Hematol 67(1): 8-15. Galli, A., G. Svegliati-Baroni, et al. (2005). 'Oxidative stress stimulates proliferation and invasiveness of hepatic stellate cells via a MMP2-mediated mechanism.' Hepatology 41(5): 1074-1084. Gallucci, R. M., P. P. Simeonova, et al. (2000). 'TNF-alpha regulates transforming growth factor-alpha expression in regenerating murine liver and isolated hepatocytes.' J Immunol 164(2): 872-878. Gao, L., M. A. Cueto, et al. (2002). 'Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family.' J Biol Chem 277(28): 25748-25755. Gao, Y. S., C. C. Hubbert, et al. (2010). 'The microtubule-associated histone deacetylase 6 (HDAC6) regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation.' J Biol Chem 285(15): 11219-11226. Giannelli, G., C. Sgarra, et al. (2008). 'EGFR and VEGFR as potential target for biological therapies in HCC cells.' Cancer Lett 262(2): 257-264. Glaser, K. B., J. Li, et al. (2003). 'Role of class I and class II histone deacetylases in carcinoma cells using siRNA.' Biochem Biophys Res Commun 310(2): 529-536. Gomaa, A. I., S. A. Khan, et al. (2008). 'Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis.' World J Gastroenterol 14(27): 4300-4308. Haggarty, S. J., K. M. Koeller, et al. (2003). 'Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation.' Proc Natl Acad Sci U S A 100(8): 4389-4394. Halkidou, K., L. Gaughan, et al. (2004). 'Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer.' Prostate 59(2): 177-189. Herold, C., M. Ganslmayer, et al. (2002). 'The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells.' J Hepatol 36(2): 233-240. Hertl, M. and A. B. Cosimi (2005). 'Liver transplantation for malignancy.' Oncologist 10(4): 269-281. Hino, O., K. Kajino, et al. (2002). 'Understanding the hypercarcinogenic state in chronic hepatitis: a clue to the prevention of human hepatocellular carcinoma.' J Gastroenterol 37(11): 883-887. Hopfner, M., D. Schuppan, et al. (2008). 'Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer.' World J Gastroenterol 14(1): 1-14. Hsu, I. C., R. A. Metcalf, et al. (1991). 'Mutational hotspot in the p53 gene in human hepatocellular carcinomas.' Nature 350(6317): 427-428. Hu, E., E. Dul, et al. (2003). 'Identification of novel isoform-selective inhibitors within class I histone deacetylases.' J Pharmacol Exp Ther 307(2): 720-728. Huang, B. H., M. Laban, et al. (2005). 'Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1.' Cell Death Differ 12(4): 395-404. Huang, X., L. Gao, et al. (2009). 'HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression.' Cancer Res 69(21): 8403-8411. Hubbert, C., A. Guardiola, et al. (2002). 'HDAC6 is a microtubule-associated deacetylase.' Nature 417(6887): 455-458. Huh, C. G., V. M. Factor, et al. (2004). 'Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair.' Proc Natl Acad Sci U S A 101(13): 4477-4482. Ishii, S., Y. Kurasawa, et al. (2008). 'Histone deacetylase 3 localizes to the mitotic spindle and is required for kinetochore-microtubule attachment.' Proc Natl Acad Sci U S A 105(11): 4179-4184. Ito, Y., T. Takeda, et al. (2001). 'Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma.' Br J Cancer 84(10): 1377-1383. Jo, M., D. B. Stolz, et al. (2000). 'Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells.' J Biol Chem 275(12): 8806-8811. Johnstone, R. W. (2002). 'Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.' Nat Rev Drug Discov 1(4): 287-299. Jorissen, R. N., F. Walker, et al. (2003). 'Epidermal growth factor receptor: mechanisms of activation and signalling.' Exp Cell Res 284(1): 31-53. Karagianni, P. and J. Wong (2007). 'HDAC3: taking the SMRT-N-CoRrect road to repression.' Oncogene 26(37): 5439-5449. Kelly, W. K. and P. A. Marks (2005). 'Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid.' Nat Clin Pract Oncol 2(3): 150-157. Kew, M. C. (2003). 'Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis.' Liver Int 23(6): 405-409. Kim, C. M., K. Koike, et al. (1991). 'HBx gene of hepatitis B virus induces liver cancer in transgenic mice.' Nature 351(6324): 317-320. Kiss, A., N. J. Wang, et al. (1997). 'Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas.' Clin Cancer Res 3(7): 1059-1066. Lavanchy, D. (2004). 'Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.' J Viral Hepat 11(2): 97-107. Leder, A., S. Orkin, et al. (1975). 'Differentiation of erythroleukemic cells in the presence of inhibitors of DNA synthesis.' Science 190(4217): 893-894. Lee, D., R. S. Pearsall, et al. (2004). 'Epiregulin is not essential for development of intestinal tumors but is required for protection from intestinal damage.' Mol Cell Biol 24(20): 8907-8916. Lee, H. B., H. Noh, et al. (2007). 'Histone deacetylase inhibitors: a novel class of therapeutic agents in diabetic nephropathy.' Kidney Int Suppl(106): S61-66. Lin, C. Y., C. J. Lin, et al. (2006). 'Macrophage activation increases the invasive properties of hepatoma cells by destabilization of the adherens junction.' FEBS Lett 580(13): 3042-3050. Llovet, J. M. and J. Bruix (2008). 'Molecular targeted therapies in hepatocellular carcinoma.' Hepatology 48(4): 1312-1327. Llovet, J. M., S. Ricci, et al. (2008). 'Sorafenib in advanced hepatocellular carcinoma.' N Engl J Med 359(4): 378-390. Lok, A. S., E. J. Heathcote, et al. (2001). 'Management of hepatitis B: 2000--summary of a workshop.' Gastroenterology 120(7): 1828-1853. Longworth, M. S. and L. A. Laimins (2006). 'Histone deacetylase 3 localizes to the plasma membrane and is a substrate of Src.' Oncogene 25(32): 4495-4500. Lu, Y. S., Y. Kashida, et al. (2007). 'Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma.' Hepatology 46(4): 1119-1130. Luger, K., A. W. Mader, et al. (1997). 'Crystal structure of the nucleosome core particle at 2.8 A resolution.' Nature 389(6648): 251-260. Macdonald, A., K. Crowder, et al. (2003). 'The hepatitis C virus non-structural NS5A protein inhibits activating protein-1 function by perturbing ras-ERK pathway signaling.' J Biol Chem 278(20): 17775-17784. Madshus, I. H. and E. Stang (2009). 'Internalization and intracellular sorting of the EGF receptor: a model for understanding the mechanisms of receptor trafficking.' J Cell Sci 122(Pt 19): 3433-3439. Maeda, T., M. Towatari, et al. (2000). 'Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells.' Blood 96(12): 3847-3856. Magner, W. J., A. L. Kazim, et al. (2000). 'Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors.' J Immunol 165(12): 7017-7024. Majumder, M., A. K. Ghosh, et al. (2001). 'Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner.' J Virol 75(3): 1401-1407. Marks, P., R. A. Rifkind, et al. (2001). 'Histone deacetylases and cancer: causes and therapies.' Nat Rev Cancer 1(3): 194-202. Marks, P. A., T. Miller, et al. (2003). 'Histone deacetylases.' Curr Opin Pharmacol 3(4): 344-351. Marks, P. A., V. M. Richon, et al. (2000). 'Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells.' J Natl Cancer Inst 92(15): 1210-1216. Marks, P. A., M. Sheffery, et al. (1987). 'Induction of transformed cells to terminal differentiation and the modulation of gene expression.' Cancer Res 47(3): 659-666. Marrero, C. R. and J. A. Marrero (2007). 'Viral hepatitis and hepatocellular carcinoma.' Arch Med Res 38(6): 612-620. Marrogi, A. J., M. A. Khan, et al. (2001). 'Oxidative stress and p53 mutations in the carcinogenesis of iron overload-associated hepatocellular carcinoma.' J Natl Cancer Inst 93(21): 1652-1655. Masui, H., T. Kawamoto, et al. (1984). 'Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies.' Cancer Res 44(3): 1002-1007. Maxwell, P. H. (2005). 'The HIF pathway in cancer.' Semin Cell Dev Biol 16(4-5): 523-530. McClain, C. J., D. B. Hill, et al. (2002). 'Monocyte activation in alcoholic liver disease.' Alcohol 27(1): 53-61. Michaelis, M., U. R. Michaelis, et al. (2004). 'Valproic acid inhibits angiogenesis in vitro and in vivo.' Mol Pharmacol 65(3): 520-527. Minucci, S. and P. G. Pelicci (2006). 'Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.' Nat Rev Cancer 6(1): 38-51. Mitchell, C., M. Nivison, et al. (2005). 'Heparin-binding epidermal growth factor-like growth factor links hepatocyte priming with cell cycle progression during liver regeneration.' J Biol Chem 280(4): 2562-2568. Moinzadeh, P., K. Breuhahn, et al. (2005). 'Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade--results of an explorative CGH meta-analysis.' Br J Cancer 92(5): 935-941. Monvoisin, A., V. Neaud, et al. (1999). 'Direct evidence that hepatocyte growth factor-induced invasion of hepatocellular carcinoma cells is mediated by urokinase.' J Hepatol 30(3): 511-518. Morimitsu, Y., C. C. Hsia, et al. (1995). 'Nodules of less-differentiated tumor within or adjacent to hepatocellular carcinoma: relative expression of transforming growth factor-alpha and its receptor in the different areas of tumor.' Hum Pathol 26(10): 1126-1132. Moriya, K., K. Nakagawa, et al. (2001). 'Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis.' Cancer Res 61(11): 4365-4370. Munshi, N., S. Jeay, et al. (2010). 'ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.' Mol Cancer Ther 9(6): 1544-1553. Nakanishi, K., J. Fujimoto, et al. (1999). 'Hepatocyte growth factor promotes migration of human hepatocellular carcinoma via phosphatidylinositol 3-kinase.' Clin Exp Metastasis 17(6): 507-514. Naresh, A., W. Long, et al. (2006). 'The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells.' Cancer Res 66(12): 6412-6420. Natarajan, A., B. Wagner, et al. (2007). 'The EGF receptor is required for efficient liver regeneration.' Proc Natl Acad Sci U S A 104(43): 17081-17086. Nightingale, K. P., L. P. O'Neill, et al. (2006). 'Histone modifications: signalling receptors and potential elements of a heritable epigenetic code.' Curr Opin Genet Dev 16(2): 125-136. Nijhara, R., S. S. Jana, et al. (2001). 'Sustained activation of mitogen-activated protein kinases and activator protein 1 by the hepatitis B virus X protein in mouse hepatocytes in vivo.' J Virol 75(21): 10348-10358. Nowak, M. A., S. Bonhoeffer, et al. (1996). 'Viral dynamics in hepatitis B virus infection.' Proc Natl Acad Sci U S A 93(9): 4398-4402. Nusinzon, I. and C. M. Horvath (2003). 'Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1.' Proc Natl Acad Sci U S A 100(25): 14742-14747. Ocker, M., A. Alajati, et al. (2005). 'The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells.' J Cancer Res Clin Oncol 131(6): 385-394. Ogawa, K., S. Yasumura, et al. (2004). 'Sodium butyrate enhances Fas-mediated apoptosis of human hepatoma cells.' J Hepatol 40(2): 278-284. Okano, H., K. Shiraki, et al. (2003). 'Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma.' Lab Invest 83(7): 1033-1043. Ortiz, C., L. Caja, et al. (2008). 'Inhibition of the EGF receptor blocks autocrine growth and increases the cytotoxic effects of doxorubicin in rat hepatoma cells: role of reactive oxygen species production and glutathione depletion.' Biochem Pharmacol 75(10): 1935-1945. Osna, N. A., D. L. Clemens, et al. (2005). 'Ethanol metabolism alters interferon gamma signaling in recombinant HepG2 cells.' Hepatology 42(5): 1109-1117. Ozturk, M. (1991). 'p53 mutation in hepatocellular carcinoma after aflatoxin exposure.' Lancet 338(8779): 1356-1359. Pachiadakis, I., G. Pollara, et al. (2005). 'Is hepatitis C virus infection of dendritic cells a mechanism facilitating viral persistence?' Lancet Infect Dis 5(5): 296-304. Pandolfi, P. P. (2001). 'Histone deacetylases and transcriptional therapy with their inhibitors.' Cancer Chemother Pharmacol 48 Suppl 1: S17-19. Papeleu, P., P. Loyer, et al. (2003). 'Trichostatin A induces differential cell cycle arrests but does not induce apoptosis in primary cultures of mitogen-stimulated rat hepatocytes.' J Hepatol 39(3): 374-382. Park, W. S., S. M. Dong, et al. (1999). 'Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas.' Cancer Res 59(2): 307-310. Pasqualucci, L., O. Bereschenko, et al. (2003). 'Molecular pathogenesis of non-Hodgkin's lymphoma: the role of Bcl-6.' Leuk Lymphoma 44 Suppl 3: S5-12. Peart, M. J., G. K. Smyth, et al. (2005). 'Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors.' Proc Natl Acad Sci U S A 102(10): 3697-3702. Peart, M. J., K. M. Tainton, et al. (2003). 'Novel mechanisms of apoptosis induced by histone deacetylase inhibitors.' Cancer Res 63(15): 4460-4471. Pennacchietti, S., P. Michieli, et al. (2003). 'Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene.' Cancer Cell 3(4): 347-361. Philip, P. A., M. R. Mahoney, et al. (2005). 'Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.' J Clin Oncol 23(27): 6657-6663. Prigent, S. A. and W. J. Gullick (1994). 'Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera.' EMBO J 13(12): 2831-2841. Qian, D. Z., Y. Kato, et al. (2006). 'Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.' Clin Cancer Res 12(2): 634-642. Reddy, P., Y. Maeda, et al. (2004). 'Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect.' Proc Natl Acad Sci U S A 101(11): 3921-3926. Rehermann, B. and M. Nascimbeni (2005). 'Immunology of hepatitis B virus and hepatitis C virus infection.' Nat Rev Immunol 5(3): 215-229. Richon, V. M., R. G. Ramsay, et al. (1989). 'Modulation of the c-myb, c-myc and p53 mRNA and protein levels during induced murine erythroleukemia cell differentiation.' Oncogene 4(2): 165-173. Riggs, M. G., R. G. Whittaker, et al. (1977). 'n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells.' Nature 268(5619): 462-464. Rikimaru, T., A. Taketomi, et al. (2007). 'Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma.' Oncology 72(1-2): 69-74. Roberts, L. R. and G. J. Gores (2005). 'Hepatocellular carcinoma: molecular pathways and new therapeutic targets.' Semin Liver Dis 25(2): 212-225. Rosen, E. M. and I. D. Goldberg (1995). 'Scatter factor and angiogenesis.' Adv Cancer Res 67: 257-279. Roth, S. Y., J. M. Denu, et al. (2001). 'Histone acetyltransferases.' Annu Rev Biochem 70: 81-120. Ruefli, A. A., M. J. Ausserlechner, et al. (2001). 'The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species.' Proc Natl Acad Sci U S A 98(19): 10833-10838. Russell, W. E., W. K. Kaufmann, et al. (1996). 'Liver regeneration and hepatocarcinogenesis in transforming growth factor-alpha-targeted mice.' Mol Carcinog 15(3): 183-189. Sagmeister, S., C. Drucker, et al. (2008). 'HB-EGF is a paracrine growth stimulator for early tumor prestages in inflammation-associated hepatocarcinogenesis.' J Hepatol 49(6): 955-964. Sartor, C. I., H. Zhou, et al. (2001). 'Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells.' Mol Cell Biol 21(13): 4265-4275. Sasakawa, Y., Y. Naoe, et al. (2003). 'Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors.' Biochem Pharmacol 66(6): 897-906. Sasaki, M., H. Ikeda, et al. (2008). 'The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma.' Lab Invest 88(8): 873-882. Schiffer, E., C. Housset, et al. (2005). 'Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis.' Hepatology 41(2): 307-314. Schmidt, C., F. Bladt, et al. (1995). 'Scatter factor/hepatocyte growth factor is essential for liver development.' Nature 373(6516): 699-702. Seol, D. W., Q. Chen, et al. (2000). 'Transcriptional activation of the hepatocyte growth factor receptor (c-met) gene by its ligand (hepatocyte growth factor) is mediated through AP-1.' Oncogene 19(9): 1132-1137. Sergina, N. V., M. Rausch, et al. (2007). 'Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.' Nature 445(7126): 437-441. Shepard, H. M., C. M. Brdlik, et al. (2008). 'Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family.' J Clin Invest 118(11): 3574-3581. Sherman, M. (2005). 'Hepatocellular carcinoma: epidemiology, risk factors, and screening.' Semin Liver Dis 25(2): 143-154. Shimoda, R., M. Nagashima, et al. (1994). 'Increased formation of oxidative DNA damage, 8-hydroxydeoxyguanosine, in human livers with chronic hepatitis.' Cancer Res 54(12): 3171-3172. Shin, E. C., J. S. Shin, et al. (1998). 'Expression of Fas-related genes in human hepatocellular carcinomas.' Cancer Lett 134(2): 155-162. Sibilia, M., R. Kroismayr, et al. (2007). 'The epidermal growth factor receptor: from development to tumorigenesis.' Differentiation 75(9): 770-787. Skov, S., M. T. Pedersen, et al. (2005). 'Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B.' Cancer Res 65(23): 11136-11145. Soltoff, S. P., K. L. Carraway, 3rd, et al. (1994). 'ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor.' Mol Cell Biol 14(6): 3550-3558. Sorkin, A. and L. K. Goh (2008). 'Endocytosis and intracellular trafficking of ErbBs.' Exp Cell Res 314(17): 3093-3106. Sparmann, A. and M. van Lohuizen (2006). 'Polycomb silencers control cell fate, development and cancer.' Nat Rev Cancer 6(11): 846-856. Spurling, C. C., C. A. Godman, et al. (2008). 'HDAC3 overexpression and colon cancer cell proliferation and differentiation.' Mol Carcinog 47(2): 137-147. Strahl, B. D. and C. D. Allis (2000). 'The language of covalent histone modifications.' Nature 403(6765): 41-45. Suzuki, A., M. Hayashida, et al. (2000). 'Hepatocyte growth factor promotes cell survival from fas-mediated cell death in hepatocellular carcinoma cells via Akt activation and Fas-death-inducing signaling complex suppression.' Hepatology 32(4 Pt 1): 796-802. Suzuki, K., N. Hayashi, et al. (1994). 'Expression of the c-met protooncogene in human hepatocellular carcinoma.' Hepatology 20(5): 1231-1236. Svechnikova, I., S. G. Gray, et al. (2003). 'Apoptosis and tumor remission in liver tumor xenografts by 4-phenylbutyrate.' Int J Oncol 22(3): 579-588. Takami, T., P. Kaposi-Novak, et al. (2007). 'Loss of hepatocyte g | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/45695 | - |
dc.description.abstract | 肝癌為全世界第五大常見癌症,高居癌症死亡之第三位,且缺乏有效的藥物治療。許多文獻證實,生長因子受體EGFR與c-Met在肝癌均有過度表現,可活化細胞生長之訊號導致癌化。觀察不同HDAC isoform在肝腫瘤細胞株之表現,發現HDAC3表現量與EGFR及c-Met蛋白表現正相關,Huh7細胞之HDAC3表現較多,EGFR、c-Met表現量亦較高。肝腫瘤細胞處理廣效型HDAC抑制劑SAHA在in vitro及in vivo均有抗肝臟腫瘤細胞生長之作用,增加p21表現、引發G2/M arrest及促進細胞凋亡。SAHA亦能抑制EGFR、c-Met蛋白之表現,且SAHA之PARP cleavage和p21增加作用與其抑制EGFR表現相關。將帶有shRNA基因片段之病毒載體感染肝癌細胞,藉由RNA干擾移除HDAC1、2、3和8之基因表現,發現knockdown HDAC3會引發G2/M arrest,並影響EGFR、c-Met蛋白之穩定性,此作用可能是經由促進配體誘發之內吞作用而加速生長因子受體之分解。肝癌細胞給予SAHA或knockdown HDAC3均可抑制EGF誘發之細胞生長,亦可抑制EGF、HGF刺激引發之Akt訊號傳遞。由於HER3之活化可能導致抗藥性的產生,我們進一步發現SAHA或knockdown HDAC3均可抑制HER3蛋白之表現及其磷酸化;將SAHA併用sorafenib在in vitro及in vivo均有較好之腫瘤抑制效果。總結以上結果,HDAC3在調控肝癌細胞生長扮演重要角色,SAHA抑制HDAC3會造成細胞週期之G2/M arrest,使EGFR、c-Met及HER3蛋白之表現降低,並抑制Akt及HER3之磷酸化,進而阻斷調控肝臟腫瘤細胞增生之訊號傳遞。 | zh_TW |
dc.description.abstract | Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer death worldwide. Effective therapeutic options for HCC are limited. There is a large body of evidence that overexpression of EGFR and c-Met contributes to aberrant activation of cell proliferation signaling cascade in human hepatocarcinogenesis. We analyzed distinct expression profiles of HDAC isozymes among HCC cell lines and found that Huh7 expressed higher level of EGFR and c-Met in accordance with an abundance of HDAC3. The pan-HDAC inhibitor SAHA exhibited antitumor effects in vitro and in vivo and induced upregulation of p21, G2/M arrest as well as apoptosis. SAHA also reduced EGFR and c-Met protein expression. Downregulation of EGFR was involved in the SAHA-induced PARP cleavage and increase in p21. When HDAC1, 2, 3 or 8 was knockdown by respective lentiviral vector-expressed shRNA, depletion of HDAC3 was found to lead to the accumulation of cells in G2/M phase. Protein stability of EGFR and c-Met was reduced as well and probably resulted from the accelerated ligand-induced receptor degradation. SAHA or knockdown of HDAC3 inhibited the EGF-induced cell proliferation and the EGF/HGF-induced phosphorylation of Akt. Since HER3 has been reported to mediate drug resistance in many cancers, the HER3 level was analyzed and found that its protein expression and phosphorylation were reduced by SAHA and knockdown of HDAC3. Moreover, SAHA in combination with sorafenib exhibited an improved antitumor effect both in vitro and in vivo. Taken together, our data demonstrated the important role of HDAC3 in the regulation of HCC cell proliferation and survival. Depletion of HDAC3 by SAHA induces G2/M arrest and leads to the downregulation of EGFR, c-Met and HER3, resulting in the inhibition of cell proliferation by blocking Akt and HER3 phosphorylation. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T04:44:45Z (GMT). No. of bitstreams: 1 ntu-99-R97443014-1.pdf: 6695084 bytes, checksum: 819c9a4e702e2791201e727f1aa6d0e4 (MD5) Previous issue date: 2010 | en |
dc.description.tableofcontents | 目錄
縮寫表 i 中文摘要 iv Abstract v 第一章 緒論 1 第一節 Hepatocellular carcinoma (HCC) 1 Epidemiology 1 Etiologies of HCC 1 Tumor Staging and Therapies 4 第二節 Dsregulation of growth factor signaling in human HCC 10 EGFR signaling 10 The EGFR signaling system in chronic liver injury and cancer 11 c-Met signaling 14 HER3 mediateig drug resistance is a noval target in cancer therapy 16 第三節 Histone deacetylase inhibitors for treatment of HCC 29 Modifications of Histone 29 The histone deacetylase family (HDAC family) 30 HDACS as anticancer targets 30 Biological effects of histone deacetylase inhibitors (HDAC inhibitor;HDACi) 31 HDAC inhibitors in hepatoma model 34 研究動機 43 第二章 實驗材料與方法 45 第三章 實驗結果 59 第四章 討論 96 參考資料 102 | |
dc.language.iso | zh-TW | |
dc.title | HDAC Inhibitors抑制肝癌細胞生長因子受體表現之研究 | zh_TW |
dc.title | Studies of Growth Factor Receptors Inhibition in HCC by HDAC Inhibitors | en |
dc.type | Thesis | |
dc.date.schoolyear | 98-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 吳明賢,黃偉謙 | |
dc.subject.keyword | 肝癌,組織蛋白去乙醯酶,抑制劑,表皮生長因子接受體,肝細胞生長因子接受體, | zh_TW |
dc.subject.keyword | HCC,hepacellular carcinoma,HDAC inhibitor,EGFR,c-Met,HER3, | en |
dc.relation.page | 117 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2010-08-09 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-99-1.pdf 目前未授權公開取用 | 6.54 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。